{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:03:52Z","timestamp":1788458632627,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","award":["2001110341"],"award-info":[{"award-number":["2001110341"]}],"id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115413","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:02:05Z","timestamp":1756285325000},"page":"115413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Repurposing edaravone in oncology: Bridging antioxidant defense and immune modulation"],"prefix":"10.1016","volume":"164","author":[{"given":"Sara I.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Zaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema A.","family":"Hersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa O.","family":"Hamouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar A.","family":"Al Hindawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0005","first-page":"25","article-title":"Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Cruz","year":"2018","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0010","article-title":"Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis","volume":"vol. 14","author":"Cho","year":"2020","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.intimp.2025.115413_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052945","article-title":"Update on antioxidant therapy with Edaravone: expanding applications in neurodegenerative diseases","volume":"25","author":"Yamashita","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2025.115413_bb0020","article-title":"Synthesis, Characterization and Assessment of Antioxidant and Melanogenic Inhibitory Properties of Edaravone Derivatives","volume":"13","author":"Mohan","year":"2024","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0025","article-title":"Effects of the Edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection","volume":"11","author":"Cha","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"8","key":"10.1016\/j.intimp.2025.115413_bb0030","article-title":"Edaravone for the treatment of motor Neurone disease: a critical review of approved and alternative formulations against a proposed quality target product profile","volume":"16","author":"O'Neill","year":"2024","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.intimp.2025.115413_bb0035","first-page":"505","volume":"16","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.intimp.2025.115413_bb0040","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cpdd.925","article-title":"Evaluation of pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"10.1016\/j.intimp.2025.115413_bb0045","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cpdd.952","article-title":"Bioequivalence study of Oral suspension and intravenous formulation of Edaravone in healthy adult subjects","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"10.1016\/j.intimp.2025.115413_bb0050","article-title":"Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone","volume":"9","author":"Ismail","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/SHK.0b013e31816171f4","article-title":"Edaravone Prevents Fas-Induced Fulminant Hepatic Failure in Mice by Regulating Mitochondrial Bcl-xL and Bax","volume":"30","author":"Miyasou","year":"2008","journal-title":"Shock (Augusta, Ga.)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40659-020-00297-0","article-title":"Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK\/STAT pathway","volume":"53","author":"Zhao","year":"2020","journal-title":"Biol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115413_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031633","article-title":"Edaravone: a novel possible drug for Cancer treatment?","volume":"25","author":"Duranti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.115413_bb0070","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.freeradbiomed.2011.05.017","article-title":"Vitamins C and E: beneficial effects from a mechanistic perspective","volume":"51","author":"Traber","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/10915810601122893","article-title":"Protective role of melatonin and coenzyme Q10 in ochratoxin a toxicity in rat liver and kidney","volume":"26","author":"Sutken","year":"2007","journal-title":"Int. J. Toxicol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41398-021-01464-x","article-title":"Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders","volume":"11","author":"Melhuish Beaupre","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111592","article-title":"Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro","volume":"384","author":"Homma","year":"2019","journal-title":"Exp. Cell Res."},{"issue":"18","key":"10.1016\/j.intimp.2025.115413_bb0090","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.7150\/jca.54699","article-title":"Dual role of reactive oxygen species and their application in Cancer therapy","volume":"12","author":"Huang","year":"2021","journal-title":"J. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115413_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/biom9110735","article-title":"Role of reactive oxygen species in Cancer progression: molecular mechanisms and recent advancements","volume":"9","author":"Aggarwal","year":"2019","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0100","article-title":"Hypoxia-Induced Reactive Oxygen Species: Their Role in Cancer Resistance and Emerging Therapies to Overcome it","volume":"14","author":"Mendoza","year":"2025","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.intimp.2025.115413_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13070796","article-title":"Cancer metabolism: the role of ROS in DNA damage and induction of apoptosis in Cancer cells","volume":"13","author":"Zhao","year":"2023","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0110","doi-asserted-by":"crossref","first-page":"fcad356","DOI":"10.1093\/braincomms\/fcad356","article-title":"Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants","volume":"6","author":"Houldsworth","year":"2024","journal-title":"Brain communications"},{"issue":"3","key":"10.1016\/j.intimp.2025.115413_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3164\/jcbn.21-133","article-title":"Edaravone, a scavenger for multiple reactive oxygen species, reacts with singlet oxygen to yield 2-oxo-3-(phenylhydrazono)-butanoic acid","volume":"70","author":"Amekura","year":"2022","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.intimp.2025.115413_bb0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.freeradbiomed.2019.08.021","article-title":"Myeloperoxidase-mediated oxidation of edaravone produces an apparent non-toxic free radical metabolite and modulates hydrogen peroxide-mediated cytotoxicity in HL-60\u00a0cells","volume":"143","author":"Suh","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.intimp.2025.115413_bb0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12868-014-0125-3","article-title":"Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia","volume":"15","author":"Yuan","year":"2014","journal-title":"BMC Neurosci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115413_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105967","article-title":"Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers","volume":"77","author":"Bailly","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115413_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176317","article-title":"Edaravone alleviated allergic airway inflammation by inhibiting oxidative stress and endoplasmic reticulum stress","volume":"966","author":"Zhu","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0145","doi-asserted-by":"crossref","DOI":"10.31083\/JMCM26902","article-title":"Edaravone Inhibits Inflammation in Toll-Like Receptor 4-Stimulated PBMNCs from Multiple Sclerosis Patients","volume":"8","author":"Antunes","year":"2025","journal-title":"J. Mol. Clin. Med."},{"key":"10.1016\/j.intimp.2025.115413_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107924","article-title":"Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model","volume":"99","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115413_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.811125","article-title":"Editorial: emerging roles for type 2-associated cells and cytokines in Cancer immunity","volume":"12","author":"Schiavoni","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115413_bb0160","first-page":"2037","article-title":"Edaravone ameliorates experimental autoimmune thyroiditis in rats through HO-1-dependent STAT3\/PI3K\/Akt pathway","volume":"10","author":"Li","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.intimp.2025.115413_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/609579","article-title":"Toll-like receptor 4 activation in cancer progression and therapy","volume":"2011","author":"Oblak","year":"2011","journal-title":"Clin. Dev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115413_bb0170","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1245\/s10434-009-0325-8","article-title":"Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis","volume":"16","author":"Earl","year":"2009","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0175","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115413_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115513","article-title":"Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing","volume":"167","author":"Dong","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115413_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT pathway as a target for Cancer treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.115413_bb0190","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1007\/s00210-024-03045-3","article-title":"Edaravone dexborneol promotes M2 microglia polarization against lipopolysaccharide-induced inflammation via suppressing TLR4\/MyD88\/NF-\u03baB pathway","volume":"397","author":"Huang","year":"2024","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115413_bb0195","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2025.115413_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113607","article-title":"Multifunctional nanoparticles for immune regulation and oxidative stress alleviation in myocarditis","volume":"381","author":"Ye","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2025.115413_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115413_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"11","author":"Hudson","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115413_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081581","article-title":"Recent advances in nanoparticles-based platforms targeting the PD-1\/PD-L1 pathway for Cancer treatment","volume":"14","author":"Yu","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0220","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153323","article-title":"Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation","volume":"7","author":"Sagawa","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0225","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12951-022-01746-6","article-title":"Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment","volume":"20","author":"Wu","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115413_bb0230","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0240","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review)","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2025.115413_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153402","article-title":"Protection against chemotherapy- and radiotherapy-induced side effects: a review based on the mechanisms and therapeutic opportunities of phytochemicals","volume":"80","author":"Liu","year":"2021","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0250","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jsps.2017.12.013","article-title":"Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - exploring the armoury of obscurity","volume":"26","author":"Singh","year":"2018","journal-title":"Saudi Pharm J"},{"issue":"6","key":"10.1016\/j.intimp.2025.115413_bb0255","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1172\/JCI128994","article-title":"Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via notch and Wnt","volume":"130","author":"El-Sehemy","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.stem.2017.06.004","article-title":"ASCL1 reorganizes chromatin to direct neuronal fate and suppress Tumorigenicity of glioblastoma stem cells","volume":"21","author":"Park","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"9\u201310","key":"10.1016\/j.intimp.2025.115413_bb0265","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1101\/gad.321968.118","article-title":"Wnt and notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells","volume":"33","author":"Rajakulendran","year":"2019","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.intimp.2025.115413_bb0270","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.stemcr.2024.09.007","article-title":"Targeting glioblastoma with a brain-penetrant drug that impairs brain tumor stem cells via NLE1-Notch1 complex","volume":"19","author":"Burban","year":"2024","journal-title":"Stem Cell Rep."},{"issue":"2a","key":"10.1016\/j.intimp.2025.115413_bb0275","first-page":"1131","article-title":"MCI-186 inhibits tumor growth through suppression of EGFR phosphorylation and cell cycle arrest","volume":"25","author":"Suzuki","year":"2005","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2005.06.039","article-title":"The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB","volume":"229","author":"Kokura","year":"2005","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0285","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2009.12.020","article-title":"Edaravone, a known free radical scavenger, enhances X-ray-induced apoptosis at low concentrations","volume":"293","author":"Sasano","year":"2010","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.intimp.2025.115413_bb0290","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:APPT.0000045782.56480.6b","article-title":"Effects of antioxidants on X-ray- or hyperthermia-induced apoptosis in human lymphoma U937 cells","volume":"9","author":"Cui","year":"2004","journal-title":"Apoptosis\u202f: an international journal on programmed cell death"},{"key":"10.1016\/j.intimp.2025.115413_bb0295","doi-asserted-by":"crossref","unstructured":"R.I. Salganik, The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population, J. Am. Coll. Nutr. 20(5 Suppl) (2001) 464S\u2013472S; discussion 473S\u2013475S.","DOI":"10.1080\/07315724.2001.10719185"},{"issue":"6","key":"10.1016\/j.intimp.2025.115413_bb0300","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1269\/jrr.07061","article-title":"Free radical scavenger edaravone suppresses x-ray-induced apoptosis through p53 inhibition in MOLT-4 cells","volume":"48","author":"Sasano","year":"2007","journal-title":"J. Radiat. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0305","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/jpet.107.131391","article-title":"The radical scavenger edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) reacts with a pterin derivative and produces a cytotoxic substance that induces intracellular reactive oxygen species generation and cell death","volume":"324","author":"Arai","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/CAD.0b013e3282f24031","article-title":"Antioxidants block proteasome inhibitor function in endometrial carcinoma cells","volume":"19","author":"Llobet","year":"2008","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.intimp.2025.115413_bb0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/0109298673338322250211111422","article-title":"Molecular and biochemical evidence of Edaravone\u2019s impact on Dasatinib-induced AGS cell senescence: a promising strategy for gastric Cancer therapy","volume":"32","author":"Rahimifard","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.intimp.2025.115413_bb0320","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1748-717X-6-128","article-title":"Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its management","volume":"6","author":"Chen","year":"2011","journal-title":"Radiation oncology (London, England)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0325","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.ijrobp.2010.11.070","article-title":"Clinical outcomes of 174 nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis","volume":"82","author":"Lam","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.intimp.2025.115413_bb0330","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11060-014-1573-4","article-title":"Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial","volume":"120","author":"Tang","year":"2014","journal-title":"J. Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115413_bb0335","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7150\/thno.18219","article-title":"Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability","volume":"7","author":"Jin","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.intimp.2025.115413_bb0340","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3350\/cmh.2014.20.3.317","article-title":"Chemotherapy induced liver abnormalities: an imaging perspective","volume":"20","author":"Sharma","year":"2014","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115413_bb0345","first-page":"47","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.intimp.2025.115413_bb0350","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/fampra\/cmw051","article-title":"Association between unexplained hypoalbuminaemia and new cancer diagnoses in UK primary care patients","volume":"33","author":"Merriel","year":"2016","journal-title":"Fam. Pract."},{"key":"10.1016\/j.intimp.2025.115413_bb0355","series-title":"Study of Edaravone Dexborneol Injection in Patients With Acute Ischemic Stroke and Active Malignancies","author":"ClinicalTrials.gov","year":"2025"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:54:17Z","timestamp":1758786857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925014043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":71,"alternative-id":["S1567576925014043"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115413","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing edaravone in oncology: Bridging antioxidant defense and immune modulation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115413"}}